Acrivon Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRV research report →
Range $17 – $30
Price Chart
About the company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification.
- CEO
- Peter Blume-Jensen
- IPO
- 2022
- Employees
- 75
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on ACRV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $49.35M
- P/E
- -0.78
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 0.87
- EV/EBITDA
- -0.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -80.87%
- ROIC
- -106.37%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,356,000-34.8%
- Op Income
- $-84,114,000
- Net Income
- $-77,905,000+3.3%
- EPS
- $-2.02+3.8%
- OCF Growth
- +3.1%
- FCF Growth
- +4.5%
- 52W High
- $3.56
- 52W Low
- $0.97
- 50D MA
- $1.78
- 200D MA
- $1.74
- Beta
- 1.98
- RSI (14)
- 27
- Avg Volume
- 261.11K
No earnings-call transcripts are available for ACRV yet.
- Free Float
- 60.3%
- Shares Outstanding
- 42.85M
- Float Shares
- 25.84M
of shares held by institutions
45 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 12.23M | ▲ 3.89M |
| Sands Capital Alternatives, LLC | 2.29M | 0 |
| Acadian Asset Management LLC | 1.32M | ▲ 152.61K |
| Vanguard Capital Management LLC | 1.10M | ▲ 152.02K |
| Wellington Management Group Llp | 888.13K | 0 |
| Vanguard Group Inc | 698.86K | ▲ 72.71K |
| Two Sigma Investments, LP | 641.50K | ▲ 252.10K |
| Marshall Wace, Llp | 542.34K | ▲ 10.49K |
| Bridgeway Capital Management, LLC | 378.90K | ▲ 220.00K |
| Two Sigma Advisers, LP | 333.77K | ▲ 197.27K |
| Geode Capital Management, LLC | 296.76K | ▲ 31.52K |
| Blackrock, Inc. | 227.03K | ▼ 12.09K |
Held by 27 ETFs
Biggest fund positions in ACRV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Peterson Katharine | sell | 107 |
| Nov 17, 26 | Miller Mary | sell | 193 |
| Nov 17, 26 | Gamelin Erick | sell | 416 |
| Nov 17, 26 | Devroe Eric | sell | 628 |
| Nov 17, 26 | Blume-Jensen Peter | sell | 1,276 |
| Nov 17, 26 | Blume-Jensen Peter | sell | 504 |
| Oct 22, 26 | Miller Mary | sell | 513 |
| Oct 5, 26 | Miller Mary | sell | 294 |
| Aug 31, 26 | Levin Michaela | other | 130,000 |
| Aug 31, 26 | Levin Michaela | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACRV coverage
Recent articles, reports, and earnings notes.
No research on ACRV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACRV report →Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com · Nov 16
Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
seekingalpha.com · Nov 10
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
globenewswire.com · Nov 6
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
globenewswire.com · Nov 4
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
globenewswire.com · Oct 29
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
globenewswire.com · Oct 20
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
zacks.com · Sep 15
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
zacks.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.